HBM Healthcare Investments achieves a balanced result in the 2023/2024 financial year

HBM Healthcare Investments AG / Key word(s): Annual Results HBM Healthcare Investments achieves a balanced result in the 2023/2024 financial year 08-May-2024 / 18:37 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Slight loss of CHF 1 million Net asset value per share (NAV) 0.3% higher after share buy-backs Mixed portfolio performance Unfavourable currency developments reduce annual result by around 2.5% Portfolio selectively supplemented with investments in two private companies Board of Directors proposes unchanged par value repayment of CHF 7.50 per share

HBM Healthcare Investments almost broke even in the 2023/2024 financial year with a slight loss of CHF 1 million. The net asset value per share (NAV) rose by 0.3 percent as the number of shares outstanding was reduced by share buy-backs. The share price fell by 6.0 percent.

The performance of the portfolio was mixed. The following investments contributed the most to the NAV development:

Winner	NAV	Loser	NAV
Y-mAbs Therapeutics	1.9%	Cathay Biotech	–5.6%
Biohaven	1.2%	Farmalatam (private)